Dairy bacteria could treat inflammatory bowel disease

LONDON, September 1 (SPIS MedWire). A new treatment for inflammatory bowel disease (IBD) has been developed involving a bacterium used in the manufacture of dairy products. Scientists at the Flanders Interuniversity Institute for Biotechnology genetically modified Lactococcus lactis to produce anti-inflammatory interleukin-10 (IL-10). Administered orally in mice, the strain appeared to prevent and even cure chronic IBD. Conventional treatments administered orally or by injection are hindered bec

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

LONDON, September 1 (SPIS MedWire). A new treatment for inflammatory bowel disease (IBD) has been developed involving a bacterium used in the manufacture of dairy products. Scientists at the Flanders Interuniversity Institute for Biotechnology genetically modified Lactococcus lactis to produce anti-inflammatory interleukin-10 (IL-10). Administered orally in mice, the strain appeared to prevent and even cure chronic IBD. Conventional treatments administered orally or by injection are hindered because only small amounts of medicine actually reach the target site, and side-effects occur because large amounts enter healthy tissues. Using Lactococcus lactis to produce IL-10 overcomes these problems because the IL-10 is delivered locally to the intestine. This also prevents IL-10 being degraded in the stomach and small intestine, so 10,000 times less IL-10 is needed to possibly cure IBD.

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide

Explore a Concise Guide to Optimizing Viral Transduction

A Visual Guide to Lentiviral Gene Delivery

Takara Bio
Inventia Life Science

Inventia Life Science Launches RASTRUM™ Allegro to Revolutionize High-Throughput 3D Cell Culture for Drug Discovery and Disease Research

An illustration of differently shaped viruses.

Detecting Novel Viruses Using a Comprehensive Enrichment Panel

Twist Bio